William Wierda, MD and Nitin Jain, MD
In this video, “New CLL Therapies: For Whom and When?”, William Wierda, MD and Nitin Jain, MD consider new CLL agents in frontline, and identify future trends.
There is a lot of excitement in CLL (chronic lymphocytic leukemia), as advances in biology and the genomics are successfully improving patient care and outcomes. Highly effective approved new agents include targeted inhibitors of BCR signaling and anti-apoptotic BCL-2, and novel anti-CD20 antibodies. In the past year, we now have two novel therapeutic options for first line therapy, spearing a movement away for chemoimmunotherapy for first-line therapy. Challenges remain, however, such as patient selection, side effect management, and treatment at relapse.